Research Assistant:
Dr. Buckstein’s interventional research focuses on novel targeted biologic and immunologic therapies for hematologic malignancies focusing on myelodysplastic syndromes and acute myelogenous leukemia and improving the transfusion experience for MDS patients. Her non-interventional research focuses on impact of CHIP on chemotherapy outcomes, predictors of CVD in MDS patients, documenting QOL longitudinally in MDS patients and the impact of patient-related factors like frailty and disability on quality of life and clinical outcomes in MDS. She collaborates on health services research pertaining to ‘real-life’ outcomes for approved therapies. She is on several clinical trial steering committees and scientific advisory boards of MDS-F and LLSC.
Education
- MD 1989, Boston University, USA,
- FRCPC, 2005 and 2007, Internal Medicine and Hematology University of Toronto,
Appointments & Affiliation
- Affiliate Scientist, Odette Cancer Research Program, Sunnybrook Research Institute,
- Clinician Investigator, Odette Cancer Research Program, Sunnybrook Health Sciences Centre,
- Associate Professor, Department of Medicine, University of Toronto,
Research Foci
- Clinical trials in myeloid cancers testing novel biological agents
- Health Services
- Myeloid Cancers with focus on myelodysplastic syndromes
- Patient related factors
- Quality of life
- Transfusion experience
Affiliated Labs & Programs
Selected Publications
-
Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, Heddle N, Chodirker L, Cheung M, Mozessohn L, Yee K, Gallagher J, Parmentier A, Jamula E, McQuilten Z, Wood EM, Weinkov R, Zhang L, Mamedov A, Stanworth SJ, Lin Y. Red Cell Transfusion Thresholds in Outpatients with Myelodysplastic Syndromes: Combined Results from Two Randomized Controlled Feasibility Studies. Am J Hematol. 2024 Mar 21;99(3):473-476. PMID: 38126081. Epub 2023 Dec 21. Impact Factor 12.8. Principal Author.
-
Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen DT, Buckstein R, Brunner AM, Carraway HE, Daver NG, Maria Díez-Campelo M, De Witte TM, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Lastrebner MC, Komrokji RS, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz GF, Scheinberg P, Stauder R, Van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Consensus Proposal for Revised International Working Group Response Criteria for Higher Risk Myelodysplastic Syndromes. Blood. 2023 Apr 27;141(17):2047-2061. PMID: 36724453. Impact Factor 20.3. Coauthor or Collaborator.
-
Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Lenis M, Kirubananthaan A, Mamedov A, Zhang L, Rockwood K, Buckstein R. An MDS-specific Frailty Index Based on Cumulative Deficits Adds Independent Prognostic Information to Clinical Prognostic Scoring. Leukemia. 2020 May;34(5):1394-1406. PMID: 31811236. Epub 2019 Dec 6. Impact Factor 11.4. Senior Responsible Author.
-
Cook EK, Izukawa T, Young S, Rosen G, Jamali M, Zhang L, Johnson D, Bain E, Hilland J, Ferrone CK, Buckstein J, Francis J, Momtaz B, McNaughton AJM, Liu X, Snetsinger B, Buckstein R, Rauh MJ. Comorbid and Inflammatory Characteristics of Genetic Subtypes of Clonal Hematopoiesis. Blood Adv. 2019 Aug 27;3(16):2482-2486. PMID: 31434682. Impact Factor 7.5. Co-Senior Responsible Author.
-
Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM. Patient-related Factors Independently Impact Overall Survival in Patients with Myelodysplastic Syndromes: An MDS-CAN Prospective Study. Br J Haematol. 2016 Jul;174(1):88-101. PMID: 26991631. Epub 2016 Mar 15. Impact Factor 6.5. Principal Author.